transferred on share sale and purchase date from the seller’s connected persons ) and related services i.e. registration with Food and Drug Administration (FDA), trademark permission, product and packaging
. registration with Food and Drug Administration (FDA), trademark permission, product and packaging design, and brand building etc. to customers who are business operator in skin cares and cosmetics. In addition
international sales declined dramatically at 46.03% compared to the same period of the previous year. One of the issues was the delayed product delivery after the license was issued from China Food and Drug
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures
, e.g., supermarket, food and restaurants (only for takeaway), drug stores. Online sales continued to grow remarkably by 150.0% YoY. Gross profit margin from sale of goods improved outstandingly to
baht or 6. 56 percent from the previous year, mainly due to a decrease of drug and medical supply cost since the volume of general patients and social security patients decreased. Besides, the Company
during the year. It is expected that by the end of 2017 there will be a total of 19 cafés in operation. The expansion of the café format will be targeted in urban areas with high density population and
that by the end of 2017 there will be a total of 19 cafés in operation. The expansion of the café format will be targeted in urban areas with high density population and transport hubs e.g. train
Pop-up store, by opening specifically in many tourism places that has high density of customers while inventing new special menu for each seasonal events. During Q4/2022, the Company opened 2 additional